Needham analyst Scott Berg lowered the firm’s price target on Doximity (DOCS) to $55 from $75 but keeps a Buy rating on the shares after its “mixed” Q3 results. Competition and the regulatory environment remain topics to monitor for Doximity, but the firm believes the sell-off is overdone and creates an attractive entry point for investors, the analyst tells investors in a research note. The lower than expected Q4 guide is disappointing, but Needham remains confident that budgets will unlock as 2026 progresses and that Doximity is well-positioned to maintain strong market share.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DOCS:
- Doximity price target lowered to $40 from $70 at Piper Sandler
- Doximity price target lowered to $45 from $55 at Wells Fargo
- Doximity: Rebounding Pharma Momentum, Emerging AI Upside, and Attractive Valuation Support Renewed Growth Buy Thesis
- Doximity upgraded to Neutral from Underweight at JPMorgan
- Buy Rating on Doximity: Near‑Term Timing Headwinds Create an Attractive Entry Point Amid Durable Growth and Margin Strength